FDA approves Aerospan (Acton Pharma) for Asthma
Acton Pharmaceuticals, Inc. has announced that the FDA has approved the sNDA (Supplemental New Drug Application) for Aerospan (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of Asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older. With this approval, Acton is now planning to launch Aerospan in early 2013.
The Aerospan New Drug Application (NDA) was acquired by Acton in 2009 under a licensing agreement with Forest Laboratories, Inc. at which time Acton assumed all responsibilities associated with the development and commercialization of Aerospan.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.